Back to Journals » Drug Design, Development and Therapy » Volume 13

Original Research

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

       
Total article views   HTML views PDF downloads Totals
11,403 Dovepress* 9,763+ 1,263 11,026
PubMed Central* 1,640 368 2,008
Totals 11,403 1,631 13,034
*Since 29 March 2019
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 1 3

View citations on PubMed Central and Google Scholar